Emcure Pharmaceuticals IPO subscription status: The initial public offering (IPO) of Emcure Pharmaceuticals on the second day of bidding today was positively received by investors, and the market as a whole was robust. Individual investors, non-institutional investors, and eligible institutional purchasers have all expressed interest, which has made the offering go more smoothly.
Based on BSE data, Emcure Pharmaceuticals IPO subscription status was 4.98 times on day two.
Qualified Institutional Buyers (QIBs) received a subscription 1 time, whilst non-institutional investors received a subscription 13.67 times. The retail investor category had 3.43 subscriptions, while the employee component had 4.83 bookings.
Also Read: Emcure Pharmaceuticals IPO opens today: GMP, subscription status, review, other details. Apply or not?
According to BSE data, the Emcure Pharma IPO subscription status on the first bidding day, Wednesday, July 3, was 1.32 times.
Pune-based Emcure Pharmaceuticals is a company that carries out research, develops, manufactures, and sells pharmaceutical products globally in a variety of therapeutic areas. The offering, with shares priced between ₹960 and ₹1,008, will end on July 5.
Emcure Pharmaceuticals IPO Review
Emcure Pharmaceuticals is a strong player in the pharmaceutical industry, according to the brokerage. It will continue to grow and be profitable in the coming years by utilising its strong R&D focus, global reach, leadership in the Indian market, and responsible financial management. The issue is competitively valued when compared to other listed peers, with a P/E ratio of 36.6x. For long-term benefits, the brokerage advises SUBSCRIBING to this problem.
Master Capital Services
The brokerage made clear that the business intends to use the additional funds to reduce and eventually eliminate its long-term debt. With an emphasis on important therapeutic fields like gynaecology, the firm has traditionally gone from strength to strength. Now, in order to support its future development and increase its margins, it is trying to build even more on these strengths. In light of its listed competitors, the IPO is fairly valued, and we advise subscribing with an eye toward the long run.
Also Read: Emcure Pharmaceuticals IPO: Issue booked 4.98 times on the second bidding day. Check latest GMP, subscription status.
Emcure Pharmaceuticals IPO details
The IPO comprises of a fresh offering of ₹800 crore and an offer by existing promotersand shareholders to sell ₹1,151 crore. The value of the issue size at the top of the price band is ₹1,952 crore.
The selling shareholders in the OFS include promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta.
Furthermore, shares in the OFS will be offloaded by Pushpa Rajnikant Mehta, Bhavana Satish Mehta, Kamini Sunil Mehta, Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, and Sonali Sanjay Mehta, in addition to BC Investments IV.
The book running lead managers for the Emcure Pharma IPO are Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited. The registrar for the offering is Link Intime India Private Ltd.
Also Read: Emcure Pharmaceuticals IPO day 2: GMP, subscription status, review to allotment date. Apply or not?
Emcure Pharmaceuticals IPO GMP today
Emcure Pharma IPO GMP today is +335. This indicates Emcure Pharmaceuticals share price were trading at a premium of ₹335 in the grey market, according to investorgain.com.
Considering the upper end of the IPO price band and the current premium in the grey market, Emcure Pharma IPO expected listing price was indicated at ₹1,343 apiece, which is 33.23% higher than the IPO price of ₹1,008.
‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
Also Read: Emcure Pharma IPO: Issue fully subscribed on day 1; check subscription status, GMP and other details
Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
